Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic

OBJECTIVES: Guidelines cautioned prescribing of tumour necrosis factor inhibitors (TNFi) to patients with rheumatoid arthritis and interstitial lung disease (RA-ILD) after reports of new or worsening of ILD. Less is known about outcomes among patients with RA-ILD who receive rituximab (RTX). This st...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:RMD Open
Main Authors: Druce, Katie L, Iqbal, Kundan, Watson, Kath D, Symmons, Deborah P M, Hyrich, Kimme L, Kelly, Clive
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2017
Assuntos:
Rheumatoid Arthritis
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5604605/
https://ncbi.nlm.nih.gov/pubmed/28955489
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/rmdopen-2017-000473
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados